Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Response Evaluation Criteria in Solid Tumors”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableStudy completedNCT07319767
What this trial is testing

Comparing the TDTP-RECIST With RECIST 1.1 and Other Volumetric Evaluation Methods for Assessing the Therapeutic Efficacy of Irregular Malignant Tumors

Who this might be right for
Breast CancerPancreatic Adenocarcinoma (Ductal Adenocarcinoma)Biliary Cancer (Cholangiocarcinoma, Gall Bladder Cancer)
Shanghai Zhongshan Hospital 120
Testing effectiveness (Phase 2)WithdrawnNCT07146919
What this trial is testing

AssociatiNG Bevacizumab bEmarituzumab for GynecoLogIcal CAncer

Who this might be right for
Endometrial CarcinomaOvarian CancerCervix Cancer
Centre Leon Berard
Large-scale testing (Phase 3)Study completedNCT03413579
What this trial is testing

Evaluate Efficacy of the Association Nimotuzumab(HR3) /Cisplatin-Vinorelbine on Patients With Cervical Carcinom

Who this might be right for
Cervical Cancer
El Kendi Pharmaceuticals Manufacturing Company 37
Early research (Phase 1)Study completedNCT01443481
What this trial is testing

Pharmacokinetics (PK) of TKI258 in Cancer Patients With Normal and Impaired Hepatic Function

Who this might be right for
Solid TumorsHepatic Impairment
Novartis Pharmaceuticals 38
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07159191
What this trial is testing

Envafolimab Combined With Axitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma

Who this might be right for
Advanced Renal Cell Carcinoma (aRCC)
Peking Union Medical College Hospital 30
Testing effectiveness (Phase 2)Study completedNCT01915602
What this trial is testing

Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)

Who this might be right for
Carcinoma, Hepatocellular
Bayer 14
Not applicableUnknownNCT01703650
What this trial is testing

Role of Perfusion CT in Pancreatic Cancer

Who this might be right for
Adenocarcinoma, PancreasNeuroendocrine Carcinoma of Pancreas
Seoul National University Hospital 48
Testing effectiveness (Phase 2)Looking for participantsNCT05735717
What this trial is testing

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

Who this might be right for
Hematologic MalignancyAcute LeukemiaRemission+21 more
Masonic Cancer Center, University of Minnesota 70
Testing effectiveness (Phase 2)Study completedNCT02285179
What this trial is testing

Clinical Trial to Evaluate the Safety and Effectiveness of GDC-0032 When Given Alongside Tamoxifen

Who this might be right for
Breast Cancer
The Netherlands Cancer Institute 189
Testing effectiveness (Phase 2)Study completedNCT00802880
What this trial is testing

Dacarbazine for Metastatic Soft Tissue and Bone Sarcoma

Who this might be right for
Sarcoma
Washington University School of Medicine 80
Testing effectiveness (Phase 2)Study completedNCT00510640
What this trial is testing

Thyroid Cancer and Sunitinib

Who this might be right for
CancerThyroid Carcinoma
University Hospital, Bordeaux 71
Not applicableUnknownNCT02765620
What this trial is testing

PERCIST Criteria for Response Evaluation With Solid Tumors

Who this might be right for
Lung NeoplasmsBreast NeoplasmsColonic Neoplasms+1 more
Tianjin Medical University Cancer Institute and Hospital 150
Large-scale testing (Phase 3)Study completedNCT03063450
What this trial is testing

CheckpOiNt Blockade For Inhibition of Relapsed Mesothelioma

Who this might be right for
Mesothelioma
University of Southampton 332
Testing effectiveness (Phase 2)Temporarily pausedNCT00443573
What this trial is testing

Safety Study of Recombinant NAPc2 to Prevent Tumor Progression and Metastases in Metastatic Colon Cancer

Who this might be right for
Colon Cancer
ARCA Biopharma, Inc. 100
Not applicableStudy completedNCT02385604
What this trial is testing

The Predictive Value of CT-PET in Esophageal Cancer

Who this might be right for
Esophageal Neoplasms
St. James's Hospital, Ireland 250
Testing effectiveness (Phase 2)Study completedNCT02113800
What this trial is testing

Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II Study

Who this might be right for
Poorly Differentiated Malignant Neuroendocrine CarcinomaNeuroendocrine Carcinoma, Grade 3Neuroendocrine Carcinoma, Grade 1 [Well-differentiated Neuroendocrine Carcinoma] That Switched to G3+2 more
AIO-Studien-gGmbH
Early research (Phase 1)Temporarily pausedNCT05958199
What this trial is testing

NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7

Who this might be right for
Metastatic Malignant Neoplasm
NextPoint Therapeutics, Inc. 131
Not applicableStudy completedNCT02841865
What this trial is testing

Radiological Response of Pancreatic Neuroendocrine Tumors: Comparison Between the Choi and the RECIST Criteria

Who this might be right for
Pancreatic Neuroendocrine Tumors
Grupo Espanol de Tumores Neuroendocrinos 104
Large-scale testing (Phase 3)Not Yet RecruitingNCT06434077
What this trial is testing

Clinical Trial Protocol: Randomized Placebo-Controlled Pilot Study of GcMAF (Soloways TM) in Patients With Metastatic Breast Cancer

Who this might be right for
Breast Cancer
S.LAB (SOLOWAYS) 60
Not applicableStudy completedNCT01163305
What this trial is testing

PET-CT and Circulating Tumor Cells in Colorectal Cancer

Who this might be right for
Colorectal CancerMetastasis
Chinese University of Hong Kong 84
Next Page
40